A new era in myeloma: the advent of chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies

Abstract

T-cell re-directional therapies, including chimeric antigen receptor (CAR)-T cell and bispecific antibodies (BsA), have transformed the treatment landscape to benefit patients with multiple myeloma. A number of these novel therapies has been approved internationally, with CAR-T therapy recently approved in Australia. In this clinical perspective, we describe the development of CAR-T and BsA therapies, highlighting the clinical benefits and risks, together with the significant costs and infrastructure support required for the provision of these therapies to myeloma patients.